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Introduction
Pain is a complex and uniquely personal experience, involving 
various physiological and perceptual pathways and factors. 
Pain is distinct from nociception, the latter being defined as the 
transmission of noxious stimuli to the brain, and the numerous 
processes that drive this transmission.1 Pain is then accordingly 
described as perceiving nociception, whether arising from the 
nociceptors (nociceptive pain), the nerve itself (neuropathic 
pain), or a combination of the two (mixed pain). Pain is further 
defined as “an unpleasant sensory and emotional experience 
associated with actual or potential tissue damage, or described 
in terms of such damage,”2 and is therefore an experience by an 
individual that involves both perceptual and physiological input.
The experience of pain as we currently understand it can be 
broadly divided into four steps: transduction, transmission, 
modulation, and perception1 (Figure 1). Transduction involves 
the stimulation of nociceptors at tissue sites by various noxious 
stimuli. Transmission carries the induced action potentials via 
fast A-delta and slower C fibres to the dorsal horn of the spinal 
cord, and further on to the thalamus and finally the cerebral 
cortex. Modulation of nociceptive signals occurs by stimulation 
of descending inhibitory pathways from the brain and brainstem, 
thereby altering afferent signals that eventually reach the brain 
to be interpreted.3 Perception of nociceptive signals is very 
complex, and occurs primarily in the somatosensory, prefrontal, 
insular, and cingulate cortices.3
Pain management can be targeted at any of the above pathways 
(or combinations thereof ) and the most suitable treatment 
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Pain is a complex and unique experience. It encompasses several pathways, involving nociceptive signal generation (transduction) 
and propagation (transmission), as well as perception and modulation of the nociceptive stimuli. Nonsteroidal anti-inflammatory 
drugs (NSAIDs) primarily exert their analgesic effects through inhibition of cyclooxygenase (COX) enzymes, thereby attenuating 
prostaglandin synthesis. The COX-2 selective NSAIDs (coxibs) and aspirin have also been shown to reduce colorectal cancers, 
presumably by prostaglandin-inhibition mechanisms. Paracetamol appears to have both peripheral and central effects. The 
postulated mechanism for its peripheral effects is indirect COX inhibition, while the central effects are thought to be mediated 
by modulation of descending pain inhibition pathways. Topical analgesics are available in various formulations. The topical 
NSAIDs have the same mechanism of action as the systemic formulations, but with less systemic absorption and effects. The local 
anaesthetics provide a dense sensory block via inhibition of nerve impulse transmission, and are available in percutaneous and 
transdermal preparations. Capsicum is effective for neuropathic pain, and acts by stimulating and then desensitising peripheral 
sensory nerves.
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Figure 1: Nociceptive and pain pathways4
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modality will be determined by the type of pain, patient and 
disease factors, drug characteristics, efficacy, and tolerability. 
This 3-part series on analgesics will cover different classes of 
treatments used in pain management, and will discuss the 
mechanisms of action and place in therapy of the nonsteroidal 
anti-inflammatory drugs (NSAIDs), paracetamol, and topical 
analgesics (Part 1), opioids, tramadol, and tapentadol (Part 2), 
and antidepressants and anticonvulsants (Part 3).
Nonsteroidal anti-inflammatory drugs (NSAIDs) 
Mechanism of action
The NSAIDs comprise a heterogenous group of six major chemical 
classes of drugs that are primarily used as anti-inflammatory 
agents. The main mechanism of action of NSAIDs is inhibition 
of the formation of prostaglandins (as well as prostacyclin 
and thromboxane) from arachidonic acid via inhibition of 
cyclooxygenase enzymes 1 and 2 (COX-1 and COX-2, also known 
as prostaglandin synthase),5 (Figure 2). The nomenclature of the 
COX enzymes is slightly misleading, as the synthase enzyme has 
both a cyclooxygenase (COX) and a peroxidase (POX) binding 
site.6 
The COX-1 enzyme is variably expressed in nearly all tissues, and 
is responsible for regulating normal cellular processes.7 COX-2 is 
generally undetectable in most tissues – except for its constitutive 
expression in the brain, kidney, and bone – but is highly inducible 
in states of inflammation, leading to the production of pro-
inflammatory prostaglandins.7 While many processes contribute 
to the establishment of inflammation, the prostaglandins are 
putatively accepted as the primary inflammatory mediators. The 
various downstream effects of prostaglandin synthesis depend 
on the differential expression of COX-1 and COX-2 enzymes in 
different tissues at the sites of inflammation.8 
NSAIDs exert their effect through the inhibition of COX 
enzymes, thereby reducing the production of prostaglandins 
and diminishing nociceptive signal transduction. The selection 
and degree of COX inhibition varies, however, depending on 
the NSAID used.9 Non-selective NSAIDs, including the oxicams, 
inhibit both COX-1 and COX-2, whereas the more selective COX-
2 inhibitors (termed “coxibs”) have a much greater affinity for 
the COX-2 enzyme.10 However, apart from some data on the 
coxibs, the degree of inhibition – and even COX selectivity – 
correlates poorly with the degree of anti-inflammatory effects.9 
Consequently, while the role of COX-2 in inflammation is 
putatively considered to be integral, the effect of the enzyme’s 
inhibition on inflammation is not completely understood.
Place in therapy
The clinical efficacy of NSAIDs at equipotent doses is similar 
in the general population.11 Yet among individuals there is 
considerable variation of the different NSAIDs with regards to 
response and adverse effects.12 This is most likely due to drug 
factors, like differences in the COX-selectivity of drugs, or patient 
factors, like genetically-determined differences in individuals’ 
pharmacokinetics and pharmacodynamics.13
The effect of prostaglandin inhibition by NSAIDs has been 
shown to extend beyond inflammation-related applications, 
most notably the reduction of colorectal cancers. Several large 
systematic reviews and meta-analyses have shown that NSAID 
use is associated with a lower incidence of benign and malignant 
colorectal tumours, with the reduction estimated to be in the 
range of 20–40%.14,15,16 These studies focused primarily on 
aspirin and the coxibs, but the application may extend to other 
NSAIDs as well. Colonic tumorigenesis appears to be associated 
with prostaglandin synthesis via tumour angiogenesis, cell 
proliferation, and inhibition of apoptosis.17 Inhibition of COX 
with NSAIDs may oppose these effects, thereby preventing 
tumorigenesis and inducing apoptosis. This has formed the 
rationale for adding celecoxib, a more selective COX-2 inhibitor, 
to the treatment regimen of chemotherapy-resistant cancers.18
The effect of NSAIDs on the inhibition of inflammation also 
appears to be influenced by non-prostaglandin-mediated effects. 
The clinical relevance of these effects is still under investigation, 
but seems to be facilitated by inhibition of neutrophils19 and 
disruption of protein interactions in cell membranes.20
Inhibition of COX enzymes is also responsible for the adverse 
effects of NSAIDs, most notably gastrointestinal ulceration, 
and cardiovascular events. A 2013 meta-analysis of >  350  000 
participants has indicated that diclofenac and the coxibs were 
associated with a small increased risk of major cardiovascular 
events (2 events per 1  000 patient-years).21 This effect appears 
to be mediated by a shift in the balance between COX-1 and 
COX-2 inhibition. As the coxibs primarily inhibit COX-2, there 
is a shift to the more unopposed COX-1 thromboxane effects, 
which are vasoconstrictive and pro-aggregatory.22 This theory 
has been contested in recent years, as the more COX-1 selective 
NSAIDs – tipping the balance more equally for the COX enzymes 
–  are not all associated with a lower incidence of cardiovascular 
Figure 2: NSAID-mediated COX inhibition
COX - Cyclooxygenase 
Coxib - Selective COX-2 inhibitor 
NSAIDs - Nonsteroidal anti-inflammatory drugs
S Afr Fam Pract 2019;S6
The page number in the footer is not for bibliographic referencingwww.tandfonline.com/oemd 8
events.22 Furthermore, the addition of aspirin to the coxibs 
to antagonise the COX-1 and thromboxane effects has not 
resulted in significantly decreased cardiovascular events.22 
NSAIDs should also be used with caution in at-risk patients for 
renal, pulmonary, dermatological, and haematological adverse 
effects.23 Nonetheless, NSAIDs are generally regarded as safe if 
used for short periods at the lowest effective dose. The beneficial 
outcomes of low-dose aspirin (75–100  mg) on the prevention 
of vascular events, however, have been well described. To date, 
a one-dose-fits-all approach has generally been employed, 
but recent evidence suggests that this may not be the optimal 
strategy. An analysis of trials including >  117  000 participants 
found that low-dose aspirin was most effective in prevention 
of vascular events in participants weighing <  70  kg, whereas 
participants weighing ≥ 70 kg benefited most from aspirin doses 
of ≥ 325 mg.24
In clinical practice the selection of a specific NSAID will depend 
on various factors, including the indication and evidence-base 
for a specific NSAID’s use, adverse effect profile, and patient 
experience and preference. The need for long-term NSAID 
therapy (including the coxibs) must be re-evaluated often, and 
switching between NSAIDs may be warranted to achieve the best 
outcome for a patient given the known variability in individual 
response to different NSAIDs.
Paracetamol
Paracetamol is one of the world’s most widely used analgesics, 
and despite its ubiquitous use, the mechanism by which it elicits 
pain relief is not fully understood. It was previously thought that 
paracetamol does not inhibit prostaglandin synthesis, despite 
its pharmacological and toxicological effects indicating so. 
However, research in the last two decades suggests that it does 
indeed inhibit prostaglandin production, but only when low 
levels of inflammation are present.25 In clinical care paracetamol 
is usually effective for the pain associated with mild to moderate 
inflammation, such as sprains and contusions, but not in 
patients experiencing significant inflammation associated with 
rheumatoid arthritis or acute gout. The postulated explanation 
for this observation is the indirect inhibition of the COX enzymes 
via inhibition of its POX binding site, thereby reducing the activity 
at the COX site.6,25 This is in contrast to the direct inhibition of the 
COX binding sites with the NSAIDs and coxibs.
The analgesic effects of paracetamol appear to be mediated 
through both peripheral and central mechanisms. Peripherally, 
the reduction in prostaglandin synthesis reduces transduction 
of the sensory nerves, leading to decreased nociceptive impulse 
transmission. Centrally, paracetamol inhibits the increase in 
central nervous system prostaglandins that are induced by 
peripheral nociceptive transmission.25 Paracetamol appears 
to have some COX-2 selectivity, as evidenced by its favourable 
gastrointestinal tolerance and minimal effect on platelets, 
primarily COX-1-mediated effects.25 It was postulated that 
paracetamol inhibits COX-3, a splice variant of COX-1,26 but 
subsequent evidence refuted the clinical relevance of this 
proposed inhibition.25,27 Other central analgesic mechanisms of 
paracetamol have been proposed and these relate to stimulation 
of opioid receptors, as opioid antagonists in animal models 
reverse the analgesic activity of paracetamol.6,25 This effect 
may be mediated by opioid receptor agonism in the brain, and 
possibly also by stimulating opioid-driven descending inhibition 
pathways in the spinal cord.1 Paracetamol may also activate 
serotonin-related descending inhibition pathways in the spinal 
cord, thereby modulating nociception.6 Paracetamol has also 
been linked to activation of the endogenous cannabinoid 
system, primarily via one of its active metabolites.6,28
Paracetamol is widely used in mild to moderate pain with good 
efficacy and low toxicity at therapeutic doses. Given that the 
effects of paracetamol on the body is not yet fully understood, 
future research may uncover interesting mechanisms of action, 
particularly relating to the endogenous cannabinoid system.
Topicals analgesics
Topical analgesics are indicated for the relief of mild to moderate 
muscle and joint pain, and include the topical NSAIDs (including 
salicylates), capsicum, and local anaesthetics (LA). The latter 
are used to produce a dense sensory block for local procedures 
or pain relief. Topical analgesics exert their effects either by 
reducing transduction (NSAIDs, capsicum) or transmission (LA) 
of nociceptive signals. 
The LAs are available as percutaneous injections, or formulated 
as transdermal creams, gels, sprays, or patches. They cause a 
sensory block by inhibiting sodium channels in nerve axons, 
thereby preventing generation and propagation of nerve 
impulses.29 It inhibits these ion channels from the cytoplasmic 
side of the axon, and therefore the drug molecule first has to 
pass through the membrane in the permeable, unionised form. 
Conditions that make the local environment more acidic, such 
as abscesses, will decrease the amount of unionised drug, and 
reduce the analgesic effect.1 LAs also bind to potassium channels 
in nerves, but require much larger doses to significantly block 
these channels.30 Of note is that the LAs affect nociceptive sensory 
nerves and autonomic nerves much more readily than motor 
nerves. It was previously thought that this observation was due 
to the LAs affecting smaller diameter sensory fibres more than 
the larger diameter motor fibres.31 Newer evidence indicates 
that it is rather the distance between the nodes of Ranvier of 
myelinated nerves that designate a nerve’s susceptibility to be 
blocked, with the shorter-spaced nodes of the nociceptive fibres 
being more readily affected.29
Topical NSAIDs have the same mechanism of action as the 
systemic formulations. Penetration through the skin to the site 
of inflammation leads to a more focused site of drug action. 
Systemic absorption and subsequent adverse effects are 
lessened with topical preparations, but these systemic effects 
should always be borne in mind when prescribing topical NSAIDs. 
A recently updated Cochrane Review32 comparing 16 topical 
NSAIDs to placebo for clinically significant acute musculoskeletal 
pain relief found that diclofenac, ketoprofen, and ibuprofen were 
most effective (number needed to treat [NNT] of less than 4). All 
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lesser efficacy. Topical NSAIDs were also more efficacious in 
mild to moderate acute pain conditions, with limited effect in 
chronic musculoskeletal pain. In another Cochrane Review33 
the salicylate preparations, such as methyl salicylate, showed 
conflicting evidence, with the older, smaller studies indicating 
efficacy, whereas the newer, larger trials did not.
Capsicum is approved for the temporary relief of neuropathic 
pain, as well as minor muscle and joint pain. It acts on the slow, 
sensory C-fibres where it first stimulates (causing an intense 
burning pain), and then desensitises the nerve.34 Capsicum also 
appears to deplete substance P, an endogenous neuropeptide 
involved in nociceptive transduction and transmission.35 
Evidence for the efficacy of capsicum was published in a recent 
review,36 and found that high-concentration capsicum (8%) was 
effective for neuropathic pain relief.
Topical analgesia may serve as a single pharmacological modality 
in mild to moderate pain relief, or as part of a multimodal pain 
management strategy to reduce pill burden or adverse effects 
while still providing analgesia. The potential of the topicals 
to alter pain perception and modulation must also not be 
overlooked, as simply the act of applying a cream, gel, or plaster 
may provide pain relief unrelated to the drug itself.
Conclusion
NSAIDs, paracetamol, and the topical analgesics provide effective 
and generally safe options for mild to moderate pain. Alterations 
of peripheral nociceptive transduction and transmission are the 
main targets of effect, with paracetamol possibly modulating 
central pain pathways as well. All analgesic classes have a place 
in therapy, but this is guided by the type and severity of pain, the 
evidence-base for its use, and the patient and drug profiles.
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